MarketPeel
Insider Trading Intelligence
TL

Tien-li Lee

AARD
CHIEF EXECUTIVE OFFICER · AARDVARK THERAPEUTICS, INC. · CIK 0001940120
FILING MIX · LIFETIME75%/25%
BUYS
12
SELLS
4
TOTAL VALUE
$701.5K
COMPANIES
2
ACTIVE SINCE
Jan 2023
HOLDINGS NOW
453,851
AVG SELL PX
TRADE KIND
SHOWING 16 / 16
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 13 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Tien-li Lee, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+85.71%+17.94%+0.15%+17.78%+11.97%
14d7+71.43%+32.98%+0.08%+32.89%+37.07%
30d7+71.43%+46.19%-0.67%+46.86%+39.35%
60d7+42.86%+5.54%+0.64%+4.91%-1.97%
90d7+71.43%+32.12%+2.20%+29.92%+42.43%
180d7+0.00%-39.93%+3.37%-43.30%-42.34%
1y7(6 pending)+0.00%-9.02%+12.15%-21.18%-21.18%
2y7(7 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AARD · 203,851 shares · as of Feb 9, 2026
0387,903775,8071,163,7101,551,6132026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 12 buys / 4 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AARD
AARDVARK THERAPEUTICS, INC.
SALEGRANT
Stock grant
203,851203,851Feb 9, 2026Feb 11, 2026View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
7,000$14.49$101.4K1,551,613Dec 11, 2025Dec 12, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
SALE
Chief Executive Officer
1,22940,566Oct 15, 2025Oct 16, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
1,229$4.24$5.2K1,544,613Oct 15, 2025Oct 16, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
6,500$9.51$61.8K1,539,884Sep 15, 2025Sep 16, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
3,500$9.94$34.8K1,543,384Sep 15, 2025Sep 16, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
5,000$8.50$42.5K1,533,384Sep 12, 2025Sep 12, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
6,000$7.82$46.9K1,528,384Sep 11, 2025Sep 12, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
9,000$7.91$71.2K1,522,384Sep 10, 2025Sep 12, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
17,209$4.24$73.0K1,513,384Aug 28, 2025Aug 29, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
SALE
Chief Executive Officer
17,20941,795Aug 28, 2025Aug 29, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
549,534549,534Jun 11, 2025Jun 13, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
SALE
Chief Executive Officer
350,0020Feb 14, 2025Feb 19, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
41,3031,479,633Feb 14, 2025Feb 19, 2025View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
16,542$16.00$264.7K1,496,175Feb 14, 2025Feb 19, 2025View →
SCLX
SCILEX HOLDING CO
PURCHASEGRANT
Stock grant
250,000250,000Jan 17, 2023Jan 17, 2023View →
Other insiders · AARD
Loading peer insiders…
About this filer
CIK 0001940120
ROLE
Chief Executive Officer
PRIMARY
AARD
COMPANIES
2
ACTIVE SINCE
Jan 2023
MARKETPEEL · /INSIDER/0001940120DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback